NO329563B1 - 9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler - Google Patents

9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler Download PDF

Info

Publication number
NO329563B1
NO329563B1 NO20050127A NO20050127A NO329563B1 NO 329563 B1 NO329563 B1 NO 329563B1 NO 20050127 A NO20050127 A NO 20050127A NO 20050127 A NO20050127 A NO 20050127A NO 329563 B1 NO329563 B1 NO 329563B1
Authority
NO
Norway
Prior art keywords
estra
trien
diol
triene
homo
Prior art date
Application number
NO20050127A
Other languages
English (en)
Norwegian (no)
Other versions
NO20050127D0 (no
NO20050127L (no
Inventor
Karl-Heinrich Fritzemeier
Peter Muhn
Gerd Mueller
Dirk Kosemund
Alexander Hillisch
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NO20050127D0 publication Critical patent/NO20050127D0/no
Publication of NO20050127L publication Critical patent/NO20050127L/no
Publication of NO329563B1 publication Critical patent/NO329563B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050127A 2002-06-11 2005-01-10 9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler NO329563B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PCT/EP2003/006172 WO2003104253A2 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Publications (3)

Publication Number Publication Date
NO20050127D0 NO20050127D0 (no) 2005-01-10
NO20050127L NO20050127L (no) 2005-03-11
NO329563B1 true NO329563B1 (no) 2010-11-15

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050127A NO329563B1 (no) 2002-06-11 2005-01-10 9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler

Country Status (28)

Country Link
EP (1) EP1517914B1 (de)
JP (1) JP4615998B2 (de)
KR (1) KR101006612B1 (de)
CN (1) CN1293090C (de)
AR (1) AR040188A1 (de)
AT (1) ATE303397T1 (de)
AU (1) AU2003242683B9 (de)
BR (1) BR0312140A (de)
CA (1) CA2486495C (de)
CR (1) CR10289A (de)
CU (1) CU23414B7 (de)
DE (2) DE10226326A1 (de)
DK (1) DK1517914T3 (de)
EA (1) EA008442B1 (de)
EC (1) ECSP055530A (de)
ES (1) ES2248770T3 (de)
HR (1) HRP20050009B1 (de)
IL (1) IL165321A (de)
MX (1) MXPA04012491A (de)
NO (1) NO329563B1 (de)
PE (1) PE20040613A1 (de)
PL (1) PL209910B1 (de)
RS (1) RS50878B (de)
TW (1) TWI286140B (de)
UA (1) UA78062C2 (de)
UY (1) UY27844A1 (de)
WO (1) WO2003104253A2 (de)
ZA (1) ZA200500217B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PT1689410E (pt) * 2003-11-26 2008-08-18 Bayer Schering Pharma Ag Prevenção e tratamento de doenças cardíacas hipertensivas pelos estrogénios selectivos 8beta-vinil-estra-1,3,5(10)-trieno-3,17beta-diol e 17beta-fluoro-9alfa-vinil-estra-1,3,5(10)-trieno-3,16alfa-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20110052699A1 (en) * 2008-02-13 2011-03-03 Adrian Funke Drug delivery system with stabilising effect
EP2143432A1 (de) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-Alpha-Estratrien-Derivate als ER-Beta-selektive Liganden zur Prävention und Behandlung von Darmkrebs
JP2012509286A (ja) * 2008-11-21 2012-04-19 バイエル ファーマ アクチエンゲゼルシャフト 薬物送達システム
EP3185881B1 (de) 2014-08-26 2022-03-09 Betanien Hospital Verfahren, wirkstoffe und zusammensetzungen zur behandlung von entzündlichen erkrankungen
WO2020051329A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov

Also Published As

Publication number Publication date
ATE303397T1 (de) 2005-09-15
HRP20050009A2 (en) 2005-04-30
ECSP055530A (es) 2005-03-10
UA78062C2 (en) 2007-02-15
CA2486495A1 (en) 2003-12-18
HRP20050009B1 (hr) 2013-07-31
WO2003104253A2 (de) 2003-12-18
CU23414B7 (es) 2009-09-08
EA008442B1 (ru) 2007-06-29
WO2003104253A3 (de) 2004-09-16
NO20050127D0 (no) 2005-01-10
EP1517914B1 (de) 2005-08-31
DE50301116D1 (de) 2005-10-06
MXPA04012491A (es) 2005-06-08
BR0312140A (pt) 2005-04-05
JP4615998B2 (ja) 2011-01-19
RS50878B (sr) 2010-08-31
KR20050009745A (ko) 2005-01-25
CA2486495C (en) 2011-04-19
PL373090A1 (en) 2005-08-08
AU2003242683A1 (en) 2003-12-22
AR040188A1 (es) 2005-03-16
PL209910B1 (pl) 2011-11-30
JP2005533053A (ja) 2005-11-04
AU2003242683B9 (en) 2009-08-27
EA200401544A1 (ru) 2005-06-30
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
CR10289A (es) 2008-11-26
TWI286140B (en) 2007-09-01
CN1659181A (zh) 2005-08-24
CN1293090C (zh) 2007-01-03
EP1517914A2 (de) 2005-03-30
PE20040613A1 (es) 2004-12-01
RS107004A (sr) 2006-10-27
UY27844A1 (es) 2003-12-31
NO20050127L (no) 2005-03-11
IL165321A (en) 2009-08-03
TW200407331A (en) 2004-05-16
ZA200500217B (en) 2006-03-29
DK1517914T3 (da) 2006-01-16
ES2248770T3 (es) 2006-03-16
DE10226326A1 (de) 2004-01-15
AU2003242683B2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
US7414043B2 (en) 9-α-substituted estratrienes as selectively active estrogens
US6958327B1 (en) 18 Norsteroids as selectively active estrogens
EP1169336B1 (de) Ent-steroide als selektiv wirksame estrogene
IL152248A (en) Asteroids are converted to b8-hydrocarbyl for use as unique estrogens
CA2359660A1 (en) 16-hydroxyestratrienes as selective estrogens
AU2003242683B9 (en) 9-Alpha-substituted estratrienes as selectively active estrogen
PT1226155E (pt) 18-nor-esteróides como estrogénios selectivamente activos
ES2393942T3 (es) 16,ALFA-FLUORO-ESTRATIENOS 8-BETA- sustituidos en calidad de estrógenos selectivamente activos
US20060270845A1 (en) 16-Hydroxyestratrienes as selectively active estrogens
JP2003534248A (ja) 選択的活性エストロゲンとしての８β−ヒドロカルビル置換エストラトリエン
NZ536882A (en) 9-Alpha-substituted estratrienes as selectively active estrogens
US20050282791A1 (en) 18-nor steroids as selectively active estrogens
HK1142612A (en) 8-beta-substituted estratrienes as selectively active estrogens
AU2004201405A1 (en) Ent-Steroids as selectively active estrogens

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees